188 related articles for article (PubMed ID: 12163108)
1. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.
Riddle EL; Topham MK; Haycock JW; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2002 Aug; 449(1-2):71-4. PubMed ID: 12163108
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
3. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Sep; 298(3):1150-3. PubMed ID: 11504813
[TBL] [Abstract][Full Text] [Related]
4. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
5. Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors.
Ugarte YV; Rau KS; Riddle EL; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2003 Jul; 472(3):165-71. PubMed ID: 12871750
[TBL] [Abstract][Full Text] [Related]
6. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
Frey K; Kilbourn M; Robinson T
Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
8. Methamphetamine rapidly decreases vesicular dopamine uptake.
Brown JM; Hanson GR; Fleckenstein AE
J Neurochem; 2000 May; 74(5):2221-3. PubMed ID: 10800970
[TBL] [Abstract][Full Text] [Related]
9. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications.
Hanson GR; Sandoval V; Riddle E; Fleckenstein AE
Ann N Y Acad Sci; 2004 Oct; 1025():146-50. PubMed ID: 15542712
[TBL] [Abstract][Full Text] [Related]
10. In vivo measurement of the vesicular monoamine transporter in schizophrenia.
Taylor SF; Koeppe RA; Tandon R; Zubieta JK; Frey KA
Neuropsychopharmacology; 2000 Dec; 23(6):667-75. PubMed ID: 11063922
[TBL] [Abstract][Full Text] [Related]
11. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations.
Hogan KA; Staal RG; Sonsalla PK
J Neurochem; 2000 May; 74(5):2217-20. PubMed ID: 10800969
[TBL] [Abstract][Full Text] [Related]
12. Impact of psychostimulants on vesicular monoamine transporter function.
Fleckenstein AE; Hanson GR
Eur J Pharmacol; 2003 Oct; 479(1-3):283-9. PubMed ID: 14612158
[TBL] [Abstract][Full Text] [Related]
13. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
Eyerman DJ; Yamamoto BK
J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
[TBL] [Abstract][Full Text] [Related]
14. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
Truong JG; Newman AH; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 Nov; 504(1-2):27-32. PubMed ID: 15507217
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Staal RG; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity.
Fleckenstein AE; Gibb JW; Hanson GR
Eur J Pharmacol; 2000 Oct; 406(1):1-13. PubMed ID: 11011026
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
Truong JG; Rau KS; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2003 Aug; 474(2-3):223-6. PubMed ID: 12921866
[TBL] [Abstract][Full Text] [Related]
20. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Neurosci; 2002 Oct; 22(19):8705-10. PubMed ID: 12351745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
